SCHEMBL10012255

SCHEMBL10012255

CC(=O)OCC(=O)O[Si](C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.40
HSD17B10 Q99714 2/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.34
CHRM5 P08912 2/20 0.33
CHRM1 P11229 2/20 0.33
CHRM3 P20309 2/20 0.33
PGR P06401 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
HTR1A P08908 1/20 0.33
CHRNB2 P17787 1/20 0.33
TBXA2R P21731 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA7 P36544 1/20 0.33
CHRNA4 P43681 1/20 0.33
CHRNA10 Q9GZZ6 1/20 0.33
CHRNA9 Q9UGM1 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10009735 0.77 TSHR (0.33) HSD17B10SMN1; SMN2TSHRGAA
SCHEMBL20464036 0.77
SCHEMBL2572442 0.77
SCHEMBL10011392 0.75 TSHR (0.33) HSD17B10TSHRGAA
SCHEMBL7365892 0.74 ALDH1A1 (0.48) ALDH1A1HSD17B10LMNASMN1; SMN2CHRM5
SCHEMBL118942 0.74 ALDH1A1 (0.48) ALDH1A1HSD17B10LMNASMN1; SMN2CHRM5
SCHEMBL20464045 0.73 TDP1 (0.32) ALDH1A1HSD17B10TSHR
SCHEMBL2607864 0.72
SCHEMBL2397840 0.72 ALDH1A1 (0.47) ALDH1A1HSD17B10LMNASMN1; SMN2CHRM5
SCHEMBL10012209 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2479831-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME Ube Industries, Ltd. (JP) 2012-07-25 EP claimed
US-20120171581-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME UBE INDUSTRIES, LTD. (JP) 2012-07-05 US claimed
US-9130244-B2 Nonaqueous electrolyte solution and electrochemical element using same UBE INDUSTRIES, LTD. (JP) 2015-09-08 US disclosed
EP-2908376-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME Ube Industries, Ltd. (JP) 2015-08-19 EP disclosed
CN-102348485-B Methods for removing vicinal diols from lactic acid fermentation broth DOW CORNING 2014-06-11 CN disclosed
CN-102089405-B Additives to prevent degradation of cyclic alkene derivatives FUJIFILM ELECTRONIC MATERIALS 2013-10-16 CN disclosed
EP-2479831-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME Ube Industries, Ltd. (JP) 2012-07-25 EP disclosed
US-20120171581-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME UBE INDUSTRIES, LTD. (JP) 2012-07-05 US disclosed
CN-102348485-A Methods for removing vicinal diols from lactic acid fermentation broth DOW CORNING 2012-02-08 CN disclosed
CN-101689412-A Insulating film material, multilayer wiring board and process for producing the multilayer wiring board, and semiconductor apparatus and process for producing the semiconductor device FUJITSU LTD 2010-03-31 CN disclosed
CN-101389715-A Systems and methods for functionalizing particulates with silane-containing materials DOW CORNING (US) 2009-03-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120171581-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME SLC8A1, OR10J3, SLC8B1 ALDH1A1 2965/4885HSD17B10 1563/4885LMNA 2788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.